CompanyGraph
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
002940 · SZSE · China
alkpharm.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.9: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.65%Below 5Y avg (1.17%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
44.6%Sustainable
Last Ex-Dividend
Jun 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.67BCNY697.16M · vs all stocks (USD)
Trailing P/E
41.07xRevenue (TTM)
1.33BCNY198.09M · vs all stocks (USD)
Profit Margin
8.62%Beta
0.7100xvs all stocks
52-Week Change
-41.19%vs all stocks
Market Capitalization
4.67BCNY697.16M · vs all stocks (USD)
Enterprise Value
4.31BCNY643.17M · vs all stocks (USD)
Trailing P/E
41.07xPrice to Sales (TTM)
3.50xPrice to Book (MRQ)
2.73xEnterprise to Revenue
3.25xEnterprise to EBITDA
22.25xGross Margin
41.96%Profit Margin
8.62%Operating Margin
11.80%Return on Assets (TTM)
2.46%Return on Equity (TTM)
7.59%Revenue (TTM)
1.33BCNY198.09M · vs all stocks (USD)
Revenue per Share (TTM)
6.50CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-24.30%Gross Profit (TTM)
522.81MCNY78.01M · vs all stocks (USD)
EBITDA (TTM)
223.68MCNY33.38M · vs all stocks (USD)
Net Income (TTM)
114.44MCNY17.08M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.50%Operating Cash Flow (TTM)
294.62MCNY43.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
98.27MCNY14.66M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.65%vs all stocks
5-Year Average Dividend Yield
1.17%vs all stocks
Payout Ratio
44.64%Minority Interest (Equity)
239.94MCNYFY2025 · Dec 31, 2025Revenue
1.42BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
862.36MCNYFY2025 · Dec 31, 2025Gross Profit
562.45MCNYFY2025 · Dec 31, 2025Operating Income
203.09MCNY30.30M · vs all stocks (USD)
Pre-tax Income
180.28MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.54MCNYFY2025 · Dec 31, 2025Net Income
156.73MCNYFY2025 · Dec 31, 2025EBIT
193.28MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
273.36MCNYFY2025 · Dec 31, 2025Research & Development
144.05MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
168.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
16.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
202.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
202.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
156.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-31.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
193.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
144.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
336.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
156.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.64MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.17MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
59.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.73MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.50BCNYFY2025 · Dec 31, 2025Sale of Investments
1.45BCNYFY2025 · Dec 31, 2025Other Investing Activity
22.06MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-85.98MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
191.71MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-227.92MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-57.60MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.91MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.71MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.73MSharesUpdated Sep 19, 2026Float Shares
98.52MSharesUpdated Sep 19, 2026% Held by Insiders
49.76%vs all stocks
% Held by Institutions
1.43%vs all stocks
Total Cash (MRQ)
834.84MCNY124.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.26CNYUpdated Sep 19, 2026Total Debt (MRQ)
416.65MCNY62.17M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2191xCurrent Ratio (MRQ)
1.99xBook Value per Share (MRQ)
8.44CNYUpdated Sep 19, 2026Total Assets
2.95BCNY440.32M · vs all stocks (USD)
Total Current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Liabilities
1.08BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.46BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
270.56MCNYFY2025 · Dec 31, 2025Total Current Liabilities
813.03MCNYFY2025 · Dec 31, 2025Cash
685.24MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.17MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
687.41MCNYFY2025 · Dec 31, 2025Other Short-term Investments
102.26MCNYFY2025 · Dec 31, 2025Accounts Receivable
176.03MCNYFY2025 · Dec 31, 2025Inventory
447.47MCNYFY2025 · Dec 31, 2025Accounts Payable
434.09MCNYFY2025 · Dec 31, 2025Short-term Debt
206.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
22.96MCNYFY2025 · Dec 31, 2025Long-term Debt
242.26MCNYFY2025 · Dec 31, 2025Common Stock (Book)
201.73MCNYFY2025 · Dec 31, 2025Retained Earnings
709.12MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.87BCNY278.63M · vs all stocks (USD)
Treasury Stock
84.10MCNYFY2025 · Dec 31, 202552-Week Low
22.43CNYUpdated Sep 19, 202652-Week High
48.90CNYUpdated Sep 19, 202652-Week Change
-41.19%vs all stocks
Beta
0.7100xvs all stocks
50-Day MA
25.59CNYUpdated Sep 19, 2026200-Day MA
31.13CNYUpdated Sep 19, 2026Avg 10-Day Volume
8.69MSharesUpdated Sep 19, 2026Avg 30-Day Volume
10.85MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.5600CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.9: safe zoneNotable
Altman Z-Score: 3.90
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow